PRTN3 and rheumatoid arthritis: AuToDeCRA-2 is a non-commercial, exploratory, unblinded, randomised experimental medicine study with 5 parallel groups of ACPA-positive RA participants in an allocation ratio of 1:1:1:1:1, with the aim of demonstrating and comparing immunomodulation by TolDCCitPep.